This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1913)
- Annex to CHMP highlights(367)
- Annual Report(91)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(122)
- EPAR - All authorised presentations(1978)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2706)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(140)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(42)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Full risk management plan(0)
- EPAR - Overview(1974)
- EPAR - Paediatric investigation plan compliance statement(88)
- EPAR - Procedural steps taken and scientific information after authorisation(1887)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1974)
- EPAR - Public assessment report(1549)
- EPAR - Risk-management-plan summary(1139)
- EPAR - Scientific conclusion(1358)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(247)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(164)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(71)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Report(803)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(456)
- Medicines under additional monitoring(22)
- Minutes(1249)
- Newsletter(299)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4060)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2760)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5478)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5305)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Referrals document(2773)
- Regulatory and procedural guideline(723)
- Report(1619)
- Scientific guideline(2464)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1224)
- Summary of opinion - Initial authorisation(1674)
- Supply shortage(58)
- Template or form(480)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- Advanced therapies(1797)
- Antimicrobial resistance(270)
- Biologicals(147)
- Biosimilars(649)
- Brexit(121)
- Careers(5)
- Clinical trials(601)
- Compassionate use(17)
- Compliance and inspections(600)
- Corporate(115)
- COVID-19(899)
- Data on medicines(987)
- Early access(201)
- Fees(24)
- Generic and hybrid medicines(2187)
- Governance(707)
- Innovation(1164)
- Maximum residue limit(1001)
- Medication error(28)
- Medicines(47028)
- Medicines for use outside the EU(148)
- Medicine shortages(301)
- Mpox(39)
- Paediatrics(12241)
- Parallel distribution(15)
- Pharmacovigilance(9661)
- Procurement(132)
- Product information(6316)
- Quality of medicines(224)
- Rare diseases(8242)
- Referrals(3388)
- Regulatory and procedural guidance(3520)
- Research and development(495)
- Scientific advice(290)
- Scientific guidelines(1753)
- SME(259)
- Vaccines(1501)
- Veterinary limited markets(64)
Search results (84376)
Atazanavir Viatris (previously Atazanavir Mylan) : EPAR - All Authorised presentations
English (EN) (47.81 KB - PDF)
български (BG) (53.63 KB - PDF)
español (ES) (31.92 KB - PDF)
čeština (CS) (49.81 KB - PDF)
dansk (DA) (44.17 KB - PDF)
Deutsch (DE) (43.11 KB - PDF)
eesti keel (ET) (43.7 KB - PDF)
ελληνικά (EL) (44.02 KB - PDF)
français (FR) (15.25 KB - PDF)
hrvatski (HR) (71.34 KB - PDF)
íslenska (IS) (44.96 KB - PDF)
italiano (IT) (42.68 KB - PDF)
latviešu valoda (LV) (60.44 KB - PDF)
lietuvių kalba (LT) (63.63 KB - PDF)
magyar (HU) (62.61 KB - PDF)
Malti (MT) (34.96 KB - PDF)
Nederlands (NL) (44.65 KB - PDF)
norsk (NO) (35.61 KB - PDF)
polski (PL) (34.5 KB - PDF)
português (PT) (9.86 KB - PDF)
română (RO) (48.06 KB - PDF)
slovenčina (SK) (59.28 KB - PDF)
slovenščina (SL) (40.33 KB - PDF)
Suomi (FI) (54.37 KB - PDF)
svenska (SV) (35.22 KB - PDF)
Ryzodeg : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (227.83 KB - PDF)
Sotyktu : EPAR - Product information
English (EN) (298.35 KB - PDF)
български (BG) (380.55 KB - PDF)
español (ES) (348.39 KB - PDF)
čeština (CS) (357.71 KB - PDF)
dansk (DA) (313.02 KB - PDF)
Deutsch (DE) (330.08 KB - PDF)
eesti keel (ET) (359.38 KB - PDF)
ελληνικά (EL) (375.02 KB - PDF)
français (FR) (371.47 KB - PDF)
hrvatski (HR) (356.76 KB - PDF)
íslenska (IS) (315.83 KB - PDF)
italiano (IT) (372 KB - PDF)
latviešu valoda (LV) (505.87 KB - PDF)
lietuvių kalba (LT) (380.22 KB - PDF)
magyar (HU) (379.13 KB - PDF)
Malti (MT) (394.22 KB - PDF)
Nederlands (NL) (365.36 KB - PDF)
norsk (NO) (314.45 KB - PDF)
polski (PL) (365.43 KB - PDF)
português (PT) (315.6 KB - PDF)
română (RO) (377.87 KB - PDF)
slovenčina (SK) (391.05 KB - PDF)
slovenščina (SL) (364.49 KB - PDF)
Suomi (FI) (314.33 KB - PDF)
svenska (SV) (312.94 KB - PDF)
Nexviadyme : EPAR - Product Information
English (EN) (385.71 KB - PDF)
български (BG) (723.08 KB - PDF)
español (ES) (521.03 KB - PDF)
čeština (CS) (381.95 KB - PDF)
dansk (DA) (326.83 KB - PDF)
Deutsch (DE) (533.5 KB - PDF)
eesti keel (ET) (542.53 KB - PDF)
ελληνικά (EL) (682.19 KB - PDF)
français (FR) (644.87 KB - PDF)
hrvatski (HR) (541.64 KB - PDF)
íslenska (IS) (489.66 KB - PDF)
italiano (IT) (390.79 KB - PDF)
latviešu valoda (LV) (571.27 KB - PDF)
lietuvių kalba (LT) (434.66 KB - PDF)
magyar (HU) (632.17 KB - PDF)
Malti (MT) (738.38 KB - PDF)
Nederlands (NL) (571.55 KB - PDF)
norsk (NO) (377.01 KB - PDF)
polski (PL) (554.98 KB - PDF)
português (PT) (550.04 KB - PDF)
română (RO) (626.44 KB - PDF)
slovenčina (SK) (934.72 KB - PDF)
slovenščina (SL) (747.94 KB - PDF)
Suomi (FI) (462.06 KB - PDF)
svenska (SV) (483.62 KB - PDF)
Sotyktu : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (107.31 KB - PDF)
Rinvoq : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (149.25 KB - PDF)